评估新型药物-放射治疗组合的挑战和机会
Shelby Lane1, Charles B Simone2, Jessica Schuster3
1Radiation Oncology, Baptist Memorial Hospital, Memphis, USA.
Cureus
|March 12, 2026
概括
将新型癌症药物与放射治疗 (RT) 结合起来是有前途的,但早期临床试验面临挑战. 需要更多的研究来克服障碍,并优化这些强大的癌症治疗组合.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 癌症 药物开发 癌症 药物开发
背景情况:
- 针对性疗法和免疫疗法的进展为癌症治疗提供了新的治疗策略.
- 与新型全身性药物相结合的放射治疗 (RT) 具有提高癌症治疗疗效的潜力.
- 临床前模型表明协同作用,但早期的临床试验并没有始终显示这些益处.
研究的目的:
- 探索开展早期临床试验的挑战和障碍,这些试验将放射治疗与新型全身疗法结合起来.
- 确定阻碍这些复杂临床试验成功开发和执行的因素.
- 强调需要科学合理的试验设计,以优化组合治疗.
主要方法:
- 对结合RT与新型系统性药物的早期临床试验结果的审查.
- 对临床前试验数据与临床试验结果进行分析.
- 确定试验设计和实施中的常见障碍.
主要成果:
- 早期的临床试验将RT与包括免疫疗法在内的新药结合起来,往往未能证明预期的协同作用或添加效应.
- 在临床前发现和临床试验结果之间存在重大差异.
- 试验完成的障碍包括试验设计,患者选择和理解复杂的生物相互作用的挑战.
结论:
- 需要精心设计,科学严格的早期临床试验来研究RT和新药组合.
- 克服试验执行中的障碍对于实现将放射治疗与向疗法和免疫疗法结合的潜力至关重要.
- 通过新的组合优化放射治疗的治疗比率,需要对治疗相互作用有更深入的了解,并改进临床试验策略.
更多相关视频
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
9.2K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.6K
相关概念视频
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61